证券代码：301080 证券简称：百普赛斯 公告编号：2025-089 1、本次股东会无变更、否决提案的情形； 2、本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开情况 1、现场会议召开时间：2025 年 12 月 18 日（星期四）下午 14:30 2、网络投票时间： 通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 12 月 18 日 9:15-9:25，9:30-11:30，13:00-15:00； 北京百普赛斯生物科技股份有限公司 2025 年第五次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 本次会议采取现场表决和网络投票相结合的方式，出席本次会议的股东或股 1 东代理人共计 110 名，其中参与投票的股东或股东代理人共计 110 名，代表股份 数为 102,400,934 股，占公司有表决权股份总数的 61.2527%。 通过深圳证券交易所互联网投票系统进行网络投票的具体时间为 2025 年 12 月 18 日 9:15-15:00 期间的任意时间。 3、会议召开地点：北京市北京经济技术开发区 ...

Investment Rating - The report maintains an "Outperform" rating for several companies in the innovative drug and medical device industry, including Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical [5][6][25]. Core Insights - The report emphasizes the high prosperity in innovative drugs and continues to recommend companies with innovative pipelines that are entering a volume increase phase, maintaining "Outperform" ratings for various Biopharma/Biotech companies [5][25]. - The National Healthcare Security Administration announced the 2025 insurance drug list, which added 114 drugs, including 50 innovative drugs, further validating insurance support for innovation and indicating promising domestic demand [26][27]. Summary by Sections 1. Continuous Recommendation of Innovative Drugs and Industry Chain - The report highlights the ongoing recommendation of innovative drugs and the industry chain, with a focus on companies expected to see a revaluation due to their innovative pipelines [5][25]. - Specific companies mentioned include WuXi AppTec, WuXi XDC Cayman, Hangzhou Tigermed Consulting, and leading medical equipment companies like Beijing Chunlizhengda Medical Instruments and Lepu Medical, all rated "Outperform" [5][25]. 2. Performance of A-Shares Pharmaceutical Sector - In the second week of December 2025, the A-Shares pharmaceutical sector underperformed the market, with the SW Pharma and Biotech index falling by 1.0% compared to a 0.3% decline in the SHCOMP [8][27]. - The report notes that the premium level of the pharmaceutical sector relative to all A-Shares is at a normal level, with a current relative premium rate of 69.8% [16][27]. 3. Performance of Hong Kong and U.S. Pharmaceutical Sectors - The Hong Kong stock pharmaceutical sector underperformed the market, with the Hang Seng Healthcare index falling by 2.3%, while the U.S. stock pharmaceutical sector outperformed, with the S&P 500 Healthcare Select Sector Index rising by 0.4% [28][27].

Investment Rating - The report maintains an "Overweight" rating for the innovative pharmaceutical and medical device industry chain [3][5][6]. Core Insights - The report emphasizes the continuous recommendation of innovative drugs and medical devices, highlighting the high growth potential in the innovative pharmaceutical sector. It maintains "Overweight" ratings for companies such as Heng Rui Medicine, Hansoh Pharmaceutical, and others, indicating a potential for value re-evaluation [3][5]. - The report notes that the National Medical Insurance Administration has officially announced the 2025 medical insurance drug catalog, which includes 114 new drugs, 50 of which are first-class innovative drugs. This adjustment is seen as a validation of the support for innovation in the healthcare sector [3][5]. - The A-share pharmaceutical sector underperformed the broader market in the second week of December 2025, with the SW Pharmaceutical Biotechnology index declining by 1.0% compared to a 0.3% drop in the Shanghai Composite Index [7][18]. Summary by Sections Section 1: Continuous Recommendation of Innovative Drugs and Medical Devices - The report highlights the sustained recommendation of innovative drugs and medical devices, with a focus on companies that are expected to see performance growth and value re-evaluation [5][6]. Section 2: A-share Pharmaceutical Sector Performance - In the second week of December 2025, the A-share pharmaceutical sector's performance was weaker than the overall market, ranking 16th among the primary industries [7][18]. Section 3: Hong Kong and US Market Performance - The report indicates that the Hong Kong pharmaceutical sector also underperformed, while the US pharmaceutical sector showed stronger performance compared to the broader market [18].

Core Insights - The pharmaceutical industry is experiencing a surge in innovative products, with clear domestic demand and significant potential for international expansion [4][14][25] - Investment opportunities are concentrated in innovative drugs and their supply chains, with a notable performance from CRO/CMO and chemical pharmaceuticals [9][15][17] - The report emphasizes the importance of innovation as the primary solution to industry challenges, driven by stable demand and supportive policies [26][32][41] Industry Overview - The pharmaceutical sector has faced revenue declines, with a 0.9% year-on-year decrease in revenue for the first three quarters of 2025, and net profit down by 2.2% [15][16] - The innovative drug sector has outperformed, with CRO/CMO and chemical pharmaceuticals showing net profit growth of 31.0% and 16.6% respectively [17][18] - The overall market is characterized by low fund holdings and historical valuation bottoms, indicating high investment value [20][25] Demand and Payment Dynamics - The demand for healthcare services is steadily increasing, with a projected 5% growth in total medical visits and hospital admissions in 2024 [26][28] - The aging population is expected to drive long-term demand, with 220 million people aged 65 and above by 2050 [28][30] - The medical insurance fund's income growth has outpaced expenditure growth, leading to a significant increase in fund reserves [32][36] Financing and Market Trends - The IPO market for healthcare has rebounded, with 28 IPOs in the first three quarters of 2025, a 100% increase from the previous year [42][43] - License-out transactions have surged, with transaction numbers increasing by 41% and total amounts reaching $92 billion, indicating a robust market for innovative drug licensing [48][50] - The number of IND applications and new clinical trials for innovative drugs has been steadily increasing, with a notable rise in NDA approvals [53][57] Technological Advancements - The report highlights the emergence of new technologies such as ADC and small nucleic acids, with domestic companies leading in these areas [60] - The focus on dual antibodies and GLP-1 drugs is expected to drive significant growth, with multiple development directions emerging [9][60] - The report notes that domestic companies are increasingly recognized for their innovative capabilities, particularly in the ADC space [60]

Core Points - Baipusais has completed the industrial and commercial change registration and has reissued its business license, increasing its registered capital from 120 million yuan to 167.848198 million yuan [1] - The company has expanded its business scope in accordance with operational development needs and has revised its Articles of Association accordingly [1]

类型：其他股份有限公司（上市） 统一社会信用代码：911103025604366893 证券代码：301080 证券简称：百普赛斯 公告编号：2025-084 北京百普赛斯生物科技股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 北京百普赛斯生物科技股份有限公司（以下简称"公司"）分别于 2025 年 8 月 20 日、2025 年 9 月 16 日召开第二届董事会第二十次会议、2025 年第三次临 时股东大会，审议通过了《关于变更注册资本、经营范围并修订<公司章程>的 议案》。鉴于公司 2024 年度利润分配及资本公积金转增股本方案已实施完毕， 公司注册资本由 120,000,000 元人民币变更为 167,848,198.00 元人民币；此外， 根据经营发展需要，公司增加了经营范围并相应修订《公司章程》。具体内容详 见公司在巨潮资讯网（www.cninfo.com.cn）披露的相关公告。 一、公司新取得营业执照的相关信息 近日，公司完成了工商变更登记、《公司章程》备案等手续，并取得了北京 经济技术开发区 ...

Core Points - Beijing Baipusais Biotechnology Co., Ltd. is reducing its registered capital from RMB 167,848,198 to RMB 167,177,695 due to the completion of share repurchase and cancellation [1] - The company has notified creditors regarding the capital reduction and provided details on the claims process [1] Group 1: Capital Reduction - The total share capital has changed from 167,848,198 shares to 167,177,695 shares following the cancellation of repurchased shares [1] - The registered capital will be reduced by RMB 670,503 [1] Group 2: Creditor Notification - Creditors are required to submit their claims within 45 days from the date of the notice [1] - The submission location for claims is specified as Beijing Economic and Technological Development Zone, Hongda North Road, Building 4, 4th Floor [1] - Required documents for claim submission include original and copies of contracts or agreements proving the debt relationship, along with identification documents for both corporate and individual creditors [1]

Industry Overview - Collagen masks are mainstream skincare products focused on anti-aging and repair, utilizing collagen as the core ingredient along with auxiliary components to achieve hydration and skin barrier repair [1][2] - The Chinese mask industry is expected to reach a market size of 72.986 billion yuan in 2024, entering a period of adjustment and transformation, facing growth slowdown and intensified competition [1][6] - The collagen market is experiencing explosive growth, with a compound annual growth rate (CAGR) of 41.9% from 2020 to 2023, and retail scale expected to exceed 269.5 billion yuan by 2030 [1][7] Market Dynamics - The market structure in China shows that sheet masks remain dominant, while cream masks are rapidly growing, focusing on hydration and repair needs [1][7] - The competitive landscape features local leaders dominating, niche players breaking through, and international brands penetrating the market, with a clear price gradient and significant differentiation between high, medium, and low-end markets [1][8] Industry Chain - The upstream of the collagen mask industry primarily uses animal-derived collagen, while recombinant collagen is rapidly developing due to its high purity and compatibility with mask formulations [6][10] - The manufacturing process involves various technologies to convert raw materials into different forms and functions of mask products, with sales channels dominated by online e-commerce and deepening offline professional channels [6][10] Current Development - The Chinese mask industry is transitioning into a phase of deep integration after rapid growth, with three emerging drivers leading market changes: consumption upgrades, male skincare market expansion, and personalized demand fostering innovative scenarios [6][7] - The market size is projected to steadily grow to 76.79 billion yuan by 2025 and potentially exceed 146.42 billion yuan by 2030, indicating robust long-term growth prospects [6][7] Key Players - Major companies in the collagen mask industry include Juzi Biotechnology, Huaxi Biotechnology, and Marubi Biotechnology, leveraging differentiated technologies and channel advantages to lead the market [2][10] - The industry is characterized by a multi-faceted competitive ecosystem, with local leaders, niche players, and international brands all contributing to the market dynamics [10] Future Trends - The industry is expected to advance towards high-end technology, refined products, and standardized ecosystems, with a focus on cross-disciplinary technology integration and precise formulations [10][12] - Regulatory tightening is anticipated to accelerate the elimination of smaller brands, increasing market concentration, while leading companies will strengthen their market positions through R&D innovation and global expansion [10][14]

中国经济网北京12月8日讯百普赛斯（301080）(301080.SZ)12月5日披露了关于实际控制人之一致行动人及高级管理人员股份减持计划期限届满暨实施结果 的公告。 公司于2025年8月14日披露了《关于实际控制人之一致行动人及高级管理人员减持股份的预披露公告》(公告编号：2025-048)。公司实际控制人陈宜顶的一致 行动人苗景赟计划自2025年9月5日至2025年12月4日以集中竞价或大宗交易方式减持所持有的公司股份合计不超过400,000股(占公司当时总股本的0.24%)。公 司实际控制人陈宜顶的一致行动人安义百普赛斯企业管理咨询合伙企业(有限合伙)(原名为"上海百普赛斯企业管理咨询合伙企业(有限合伙)"，以下简称"安义 百普赛斯")、安义百普嘉乐企业管理咨询合伙企业(有限合伙)(原名为"上海百普嘉乐企业管理咨询合伙企业(有限合伙)"，以下简称"安义百普嘉乐")计划自 2025年9月5日至2025年12月4日以集中竞价或大宗交易方式减持所持有的公司股份合计不超过4,600,000股(占公司当时总股本的2.74%)。公司副总经理、董事 会秘书、财务负责人林涛计划自2025年9月5日至2025年12月4 ...

证券代码：301080 证券简称：百普赛斯 公告编号：2025-083 北京百普赛斯生物科技股份有限公司 股份减持计划期限届满暨实施结果的公告 公司实际控制人之一致行动人苗景赟先生、安义百普赛斯企业管理咨询合 伙企业（有限合伙）、安义百普嘉乐企业管理咨询合伙企业（有限合伙）及高 级管理人员林涛先生保证向本公司提供的信息内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 北京百普赛斯生物科技股份有限公司（以下简称"公司"或"本公司"）于 2025 年 8 月 14 日在巨潮资讯网（http://www.cninfo.com.cn）上披露了《关于实 际控制人之一致行动人及高级管理人员减持股份的预披露公告》（公告编号： 2025-048）。公司实际控制人陈宜顶先生的一致行动人苗景赟先生计划自 2025 年 9 月 5 日至 2025 年 12 月 4 日以集中竞价或大宗交易方式减持所持有的公司股 份合计不超过 400,000 股（占公司当时总股本的 0.24%）。公司实际控制人陈宜 顶先生的一致行动人安义百普赛斯企业管理咨询合伙企业（有 ...